 Home > Biochemistry News > Biotechnology News > First in class gastric cancer first-line therapy won CDE plans to break through treatment Zai Lab owns Chinese rights

First in class gastric cancer first-line therapy won CDE plans to break through treatment Zai Lab owns Chinese rights

 Last Update: 2021-09-12
 Source: Internet
 Author: User

Tags

cancer drug resistance

il 7 receptor

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Author: Sunshine

On September 3, the CDE official website revealed that Amgen’s FPA144 injection (bemarituzumab) is intended to be included in the breakthrough treatment product, and combined with mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) for the first-line treatment of FGFR2b overexpression (immunohistochemistry) The method detects at least 10% of tumor cells overexpressing FGFR2b), human epidermal growth factor receptor (HER2) negative locally advanced or metastatic gastric and gastroesophageal junction cancer (GEJ) patients

Gastric cancer is the third most common cancer in the world, and it is also the fifth most common cancer in the world other than non-melanoma skin cancer.

Bemarituzumab is an isoform-selective monoclonal antibody targeting FGFR2

bemarituzumab mechanism of action

Bemarituzumab was originally developed by Five Prime.

In November 2020, Five Prime announced the data of a Phase II clinical FIGHT study for the first-line treatment of gastric and gastroesophageal junction cancer (GEJ)

The results showed that the median progression-free survival (PFS) of the bemarituzumab group was 2.

In June 2021, Zai Lab announced the latest research data of the phase II clinical trial of bemarituzumab at the ASCO meeting

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.